LinkedIn Profile

Access Biothera historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:biothera 218750 May 22nd, 2019 12:00AM Biothera Pharmaceuticals, Inc. 2.3K 62.00 Open Biotechnology May 22nd, 2019 05:00PM May 22nd, 2019 05:00PM Biothera Pharmaceuticals is a privately held, clinical stage immuno-oncology company developing our proprietary immunotherapy, Imprime PGG, in combination with immune checkpoint inhibitors, or CPIs, for multiple cancer indications. Imprime PGG is a biologic innate immune modulator that activates the immune system and coordinates anti-cancer immune responses that result in increased activation of cancer-specific T cells. Preclinical studies demonstrate that Imprime PGG can enhance the efficacy of anti-cancer immune responses in combination with CPI, tumor-targeting and anti-angiogenic antibodies. The Company has clinical research agreements with Merck, Genentech and AstraZeneca to evaluate Imprime PGG in combination with CPIs in multiple cancer indications, including metastatic triple negative breast cancer, head and neck cancer and colorectal cancer. Imprime PGG has shown strong evidence of tolerability in clinical trials with more than 500 subjects, including over 400 cancer patients. For more information, visit us at www.biothera.com. Open cancer immunotherapy, pharmaceutical development, translational research, oncology, immunology, immuno-oncology, biology, clinical development Open 3388 Mike Collins Drive, Suite A Eagan MN US 55121 Biothera Health Care Health Care Equipment & Services
private:biothera 218750 Mar 18th, 2018 12:00AM Biothera Pharmaceuticals, Inc. 2.0K 73.00 Open Biotechnology Mar 18th, 2018 05:01PM Mar 18th, 2018 05:01PM Open Biothera Health Care Health Care Equipment & Services
private:biothera 218750 Feb 17th, 2018 12:00AM Biothera Pharmaceuticals, Inc. 2.0K 74.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a mid-clinical stage cancer immunotherapy that enhances the efficacy of tumor-targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies. The Company has clinical research agreements with Merck to evaluate Imprime PGG and Merck’s KEYTRUDA (pembrolizumab) in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects. For more information, visit us at www.biothera.com. Biothera Health Care Health Care Equipment & Services
private:biothera 218750 Feb 16th, 2018 12:00AM Biothera Pharmaceuticals, Inc. 2.0K 74.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a mid-clinical stage cancer immunotherapy that enhances the efficacy of tumor-targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies. The Company has clinical research agreements with Merck to evaluate Imprime PGG and Merck’s KEYTRUDA (pembrolizumab) in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects. For more information, visit us at www.biothera.com. Biothera Health Care Health Care Equipment & Services
private:biothera 218750 Feb 15th, 2018 12:00AM Biothera Pharmaceuticals, Inc. 2.0K 74.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a mid-clinical stage cancer immunotherapy that enhances the efficacy of tumor-targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies. The Company has clinical research agreements with Merck to evaluate Imprime PGG and Merck’s KEYTRUDA (pembrolizumab) in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects. For more information, visit us at www.biothera.com. Biothera Health Care Health Care Equipment & Services
private:biothera 218750 Feb 14th, 2018 12:00AM Biothera Pharmaceuticals, Inc. 2.0K 74.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a mid-clinical stage cancer immunotherapy that enhances the efficacy of tumor-targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies. The Company has clinical research agreements with Merck to evaluate Imprime PGG and Merck’s KEYTRUDA (pembrolizumab) in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects. For more information, visit us at www.biothera.com. Biothera Health Care Health Care Equipment & Services
private:biothera 218750 Feb 13th, 2018 12:00AM Biothera Pharmaceuticals, Inc. 2.0K 74.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a mid-clinical stage cancer immunotherapy that enhances the efficacy of tumor-targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies. The Company has clinical research agreements with Merck to evaluate Imprime PGG and Merck’s KEYTRUDA (pembrolizumab) in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects. For more information, visit us at www.biothera.com. Biothera Health Care Health Care Equipment & Services
private:biothera 218750 Feb 12th, 2018 12:00AM Biothera Pharmaceuticals, Inc. 2.0K 74.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a mid-clinical stage cancer immunotherapy that enhances the efficacy of tumor-targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies. The Company has clinical research agreements with Merck to evaluate Imprime PGG and Merck’s KEYTRUDA (pembrolizumab) in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects. For more information, visit us at www.biothera.com. Biothera Health Care Health Care Equipment & Services
private:biothera 218750 Feb 11th, 2018 12:00AM Biothera Pharmaceuticals, Inc. 2.0K 74.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a mid-clinical stage cancer immunotherapy that enhances the efficacy of tumor-targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies. The Company has clinical research agreements with Merck to evaluate Imprime PGG and Merck’s KEYTRUDA (pembrolizumab) in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects. For more information, visit us at www.biothera.com. Biothera Health Care Health Care Equipment & Services
private:biothera 218750 Feb 10th, 2018 12:00AM Biothera Pharmaceuticals, Inc. 2.0K 74.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a mid-clinical stage cancer immunotherapy that enhances the efficacy of tumor-targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies. The Company has clinical research agreements with Merck to evaluate Imprime PGG and Merck’s KEYTRUDA (pembrolizumab) in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects. For more information, visit us at www.biothera.com. Biothera Health Care Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.